Pharmacologic Treatment

ey0017.11-12 | Pharmacologic Treatment | ESPEYB17

11.12. A randomized, controlled trial of liraglutide for adolescents with obesity

AS Kelly , P Auerbach , M Barrientos-Perez , I Gies , PM Hale , C Marcus , LD Mastrandrea , N Prabhu , S; NN8022-4180 Trial Investigators Arslanian

To read the full abstract: N Engl J Med. 2020;382(22):21172128. doi: https://pubmed.ncbi.nlm.nih.gov/32233338/Kelly et al. randomly assigned (1:1) n =251 obese adolescents (age 12 to <18 years) to receive either liraglutide (3.0 mg), a long-acting glucagon-like peptide-1 agonist, or placebo subcutaneously once daily in addition to lifestyle therapy. Liraglutide w...

2 shares

ey0017.11-13 | Pharmacologic Treatment | ESPEYB17

11.13. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss

EA Day , RJ Ford , BK Smith , P Mohammadi-Shemirani , MR Morrow , RM Gutgesell , R Lu , AR Raphenya , M Kabiri , AG McArthur , N McInnes , S Hess , G Pare , HC Gerstein , GR Steinberg

To read the full abstract: Nat Metab 2019;1:12021208.Metformin has become a mainstay in the treatment of T2DM in over six decades of clinical use and is today one of the worlds most commonly prescribed drugs. Anti-diabetic properties of metformin rely on an inhibition of hepatic glucose output through AMPK-dependent, but also AMPK-independent effects (reviewed in (1)). Neverthel...

0 shares

ESPE Yearbook of Paediatric Endocrinology

Yearbook of Paediatric Endocrinology 2020

11. Obesity and Weight Regulation

11.12. A randomized, controlled trial of liraglutide for adolescents with obesity

11.13. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss

BiosciAbstracts